echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Medical News > Latest Medical News > The Philippines has been approved for listing of The Philippines with Ailing Pharmaceuticals Lianhua Qing plague capsules.

    The Philippines has been approved for listing of The Philippines with Ailing Pharmaceuticals Lianhua Qing plague capsules.

    • Last Update: 2020-08-12
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com
    Guide: Lianhua Qing plague products are mainly used for cold, influenza-related diseases treatment.
    recently, Shijiazhuang Yingling Pharmaceutical Co., Ltd. received the Philippine Food and Drug Administration approved the issuance of the drug registration certificate, approved the company's drug Lianhua Qing pestist capsules in line with the Philippine traditional plant medicine standardregistration.
    Lianhua Qing plague products for the leading products of Ling Pharmaceutical, the national basic drug catalog and the national medical insurance catalog (Class A) varieties, mainly used for the treatment of cold, influenza-related diseases.
    Lianhua Qing plague products have been repeatedly included in the National Health And Health Administration, the State Administration of Traditional Chinese Medicine in the cold, influenza-related diseases diagnosis and treatment program.
    2020 Lianhua qing capsules/particles are listed as recommended for the "New Coronary Virus Infection Pneumonia Treatment Program" (trial version 4/5/6/7) jointly issued by the National Health And Health Administration and the State Administration of Traditional Chinese Medicine.
    April 12, 2020, the State Drug Administration approved lianhua clear plague capsules/particles to add a "new coronavirus pneumonia light, common type" of new indications on the basis of the original approved indications.
    2019, Lianhua Qing's products achieved operating income of RMB 1,703 million, accounting for 29.24% of the total operating income of Yiling Pharmaceuticals.
    the first quarter of 2020, Lianhua Qing's products achieved operating income of RMB 1,542 million, accounting for 66.07 percent of the company's total operating income.
    so far, Lianhua Qing capsules in China's Hong Kong, Macao and Brazil, Indonesia, Canada, Mozambique, Romania, Thailand, Ecuador, Singapore, Laos, respectively, in the "Chinese medicine", "drugs", "plant medicine", "natural health products," "food supplements," "modern plant medicine", "natural medicine" and other status registered to obtain a listing license.
    .
    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.